Suppression of gene expression by targeted disruption of messenger RNA: Available options and current strategies

Stem Cells

Volumn 18, Issue 5, 2000, Pages 307-319

  Jen, Kuang Yu ^a   Gewirtz, Alan M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antisense; DNA oligonucleotide; Gene targeting; Hairpin ribozymes; Hammerhead ribozymes; RNA; Targeted gene disruption

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BCR ABL PROTEIN; DEOXYRIBONUCLEASE; DNA; LEXITROPSIN; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE; POLYAMIDE; PROTEIN TYROSINE KINASE; RIBOZYME;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; DRUG DESIGN; ENZYME ACTIVITY; ENZYME LOCALIZATION; GENE DISRUPTION; GENE REPRESSION; GENE TARGETING; GENETIC RECOMBINATION; HUMAN; KNOCKOUT GENE; NONHUMAN; REVIEW; RNA CLEAVAGE; TRIPLE HELIX;

EID: 0033834587     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.18-5-307     Document Type: Review

References (118)

1. Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation
2. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide
3. Translational control of IS10 transposition
4. A unique mechanism regulating gene expression: Translational inhibition by a complementary RNA transcript (micRNA)
5. Inhibition of thymidine kinase gene expression by anti-sense RNA: A molecular approach to genetic analysis
6. Nucleic acid therapeutics: State of the art and future prospects
7. Altering mice by homologous recombination using embryonic stem cells
8. Parallel DNA triplexes, homologous recombination, and other homology-dependent DNA interactions
9. Recent advances in gene mutagenesis by sitedirected recombination
10. DNA recombination: The replication connection
11. Triplex-mediated, in vitro targeting of psoralen photoadducts within the genome of a transgenic mouse
12. Prospects for the therapeutic use of antigene oligonucleotides
13. Mutagenesis by third-strand-directed psoralen adducts in repair-deficient human cells: High frequency and altered spectrum in a xeroderma pigmentosum variant
14. Sequence-specific arrest of primer extension on single-stranded DNA by an oligonucleotide-minor groove binder conjugate
15. Mutagenesis in mammalian calls induced by triple helix formation and transcription-coupled repair
16. DNA triplex formation selectively inhibits granulocyte-macrophage colony-stimulating factor gene expression in human T cells
17. Deoxyribonucleic acid triplex formation inhibits granulocyte macrophage colony-stimulating factor gene expression and suppresses growth in juvenile myelomonocytic leukemic cells
18. Genomic targeting and genetic conversion in cancer therapy
19. Targeted mutagenesis in mammalian cells mediated by intracellular triple helix formation
20. In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides
21. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo
22. Transcription factor decoy approach to decipher the role of NF-kappa B in oncogenesis
23. Structural basis for G.C recognition in the DNA minor groove
24. The molecular perspective: DNA
25. Progress in the design of DNA sequence-specific lexitropsins
26. Degradation of mRNA in eukaryotes
27. mRNA stability and the control of gene expression
28. RNAi and double-strand RNA
29. A silence that speaks volumes
30. RNAi: Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals
31. Genetic requirements for inheritance of RNAi in C. elegans
32. Specific interference with gene function by double-stranded RNA in early mouse development
33. Gene therapy for chronic myelogenous leukemia (CML): A retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo
34. The hammerhead ribozyme
35. Nucleic acid enzymes: Playing with a fuller deck
36. Antisense therapeutics
37. Antisense oligonucleotides as therapeutic agents
38. Antisense oligonucleotide therapeutics for human leukemia
39. Fluorescence microscopic comparison of the binding of phosphodiester and phosphorothioate (antisense) oligodeoxyribonucleotides to subcellular structures, including intermediate filaments, the endoplasmic reticulum, and the nuclear interior
40. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix
41. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: Implications for antisense technology
42. Peptide nucleic acids (PNAs): Potential antisense and anti-gene agents
43. Enhancement of strand invasion by oligonucleotides through manipulation of backbone charge
44. PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules
45. Telomerase: Anti-cancer target or just a fascinating enzyme?
46. Oligonucleotides with novel, cationic backbone substituents: Aminoethylphosphonates
47. 2'-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells
48. Ribozymes, genomics and therapeutics
49. Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes
50. Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer
51. Efficient expression by an alphavirus replicon of a functional ribozyme targeted to human immunodeficiency virus type 1
52. A kinetic and thermodynamic framework for the hammerhead ribozyme reaction
53. Kinetics and thermodynamics of intermolecular catalysis by hairpin ribozymes
54. Role of divalent metal ions in the hammerhead RNA cleavage reaction
55. The hairpin ribozyme: Discovery, two-dimensional model, and development for gene therapy
56. Recent developments in the hammerhead ribozyme field
57. The structure, function and application of the hammerhead ribozyme
58. Progress toward the structure and therapeutic use of the hairpin ribozyme
59. Hammerhead ribozyme mechanism: A ribonucleotide 5' to the substrate cleavage site is not essential
60. In vitro selection of a purine nucleotide-specific hammerheadlike ribozyme
61. A hammerhead ribozyme inhibits ADE1 gene expression in yeast
62. tRNA delivery systems for ribozymes
63. Ribozyme-mediated decrease in mumps virus nucleocapsid mRNA level and progeny in infected vero cells
64. Enzymatic and anti-sense effects of a specific anti-Ki-ras ribozyme in vitro and in cell culture
65. Inhibition of luciferase expression by synthetic hammerhead ribozymes and their cellular uptake
66. Mutagenesis of the hairpin ribozyme
67. Specificity of the hairpin ribozyme. Sequence requirements surrounding the cleavage site
68. Catalytically active geometry in the reversible circularization of 'mini-monomer' RNAs derived from the complementary strand of tobacco ringspot virus satellite RNA
69. Cross-ligation and exchange reactions catalyzed by hairpin ribozymes
70. Evidence for the role of solvated metal hydroxide in the hammerhead cleavage mechanism
71. Metal ions play a passive role in the hairpin ribozyme catalysed reaction
72. Ionic requirements for RNA binding, cleavage, and ligation by the hairpin ribozyme
73. Tertiary structure formation in the hairpin ribozyme monitored by fluorescence resonance energy transfer
74. Hairpin ribozyme cleavage catalyzed by aminoglycoside antibiotics and the polyamine spermine in the absence of metal ions
75. Intracellular RNA cleavage by the hairpin ribozyme
76. A DNA enzyme that cleaves RNA
77. A general purpose RNA-cleaving DNA enzyme
78. Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes)
79. Inhibition of infection of incoming HIV-1 virus by RNA-cleaving DNA enzyme
80. Rapid determination and quantitation of the accessibility to native RNAs by antisense oligodeoxynucleotides in murine cell extracts
81. RNA accessibility prediction: A theoretical approach is consistent with experimental studies in cell extracts
82. Real time detection of DNA.RNA hybridization in living cells
83. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides
84. Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: A comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugation
85. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides
86. Cationic liposomes improve stability and intracellular delivery of antisense oligonucleotides into CaSki cells
87. Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum [published erratum appears in Biochem Biophys Res Commun 1994;200:1769]
88. Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus
89. Water-soluble, meso-substituted cationic porphyrins - A family of compounds for cellular delivery of oligonucleotides
90. Cationic porphyrins: Novel delivery vehicles for antisense oligodeoxynucleotides
91. Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides
92. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells
93. Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: Toward a synthetic virus-like gene-transfer vehicle
94. Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide
95. Cellular cytoplasmic delivery of a polypeptide toxin by reconstituted influenza virus envelopes (virosomes)
96. Gene transfer mediated by fusion protein hemagglutinin reconstituted in cationic lipid vesicles
97. Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes)
98. In vivo delivery to tumors of DNA complexed with linear polyethylenimine
99. Polyethylenimine but not cationic lipid improves antisense activity of 3'-capped phosphodiester oligonucleotides
100. Cell cycle-dependent distribution and specific inhibitory effect of vectorized antisense oligonucleotides in cell culture
101. A small nucleolar RNA: Ribozyme hybrid cleaves a nucleolar RNA target in vivo with near-perfect efficiency
102. Ribozymes in the nucleolus
103. Antisense in abundance: The ribosome as a vehicle for antisense RNA
104. Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion
105. Temperature and salt dependence of higher order structure formation by antisense c-myc and c-myb phosphorothioate oligodeoxyribonucleotides containing tetraguanylate tracts
106. Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells
107. Impact of 3'-exonuclease stereoselectivity on the kinetics of phosphorothioate oligonucleotide metabolism
108. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
109. Phase I/pharmacokinetic trial of the novel thioxanthone SR233377 (WIN33377) on a 5-day schedule
110. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A)
111. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer
112. Pharmacokinetics and tolerability of intravenous trecovirsen (GEM 91), an antisense phosphorothioate oligonucleotide, in HIV-positive subjects
113. Clinical use of streptolysin-O to facilitate antisense oligodeoxyribonucleotide delivery for purging autografts in chronic myeloid leukaemia
114. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase
115. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies
116. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects
117. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma
118. Oligonucleotide therapeutics: A step forward